Which has better earnings & valuation, AMLX or PRTC?

PureTech Health has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amylyx Pharmaceuticals $87.37M 20.83 -$144.74M -$1.50 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is AMLX or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% PureTech Health N/A N/A N/A

Does the media prefer AMLX or PRTC?

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Amylyx Pharmaceuticals' score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PRTC or PVLA?

Palvella Therapeutics has a consensus price target of $199.53, indicating a potential upside of 68.13%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Palvella Therapeutics 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.94

Which has better valuation & earnings, PRTC or PVLA?

Palvella Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Palvella Therapeutics $42.81M 39.75 -$41.72M -$4.17 N/A

Is PRTC or PVLA more profitable?

PureTech Health's return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health N/A N/A N/A Palvella Therapeutics N/A -56.87% -42.50%

Does the media refer more to PRTC or PVLA?

In the previous week, Palvella Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Palvella Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.46 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SRPT or PRTC?

Sarepta Therapeutics presently has a consensus target price of $24.81, indicating a potential upside of 43.74%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 6 Sell rating(s) 10 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.08 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SRPT or PRTC?

PureTech Health has lower revenue, but higher earnings than Sarepta Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sarepta Therapeutics $2.20B 0.83 -$713.41M -$0.96 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media favor SRPT or PRTC?

In the previous week, Sarepta Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Sarepta Therapeutics' score of 0.61 indicating that PureTech Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SNDX or PRTC?

PureTech Health has lower revenue, but higher earnings than Syndax Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syndax Pharmaceuticals $172.35M 10.08 -$285.42M -$2.79 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media prefer SNDX or PRTC?

In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 1 mentions for PureTech Health. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat PureTech Health's score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PRTC or SEPN?

Septerna has a consensus price target of $45.78, suggesting a potential upside of 25.18%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91

Which has stronger earnings and valuation, PRTC or SEPN?

Septerna has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Septerna $72.26M 22.81 -$48.88M -$0.81 N/A

Does the media refer more to PRTC or SEPN?

In the previous week, Septerna had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Septerna and 1 mentions for PureTech Health. Septerna's average media sentiment score of 1.16 beat PureTech Health's score of 0.72 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PureTech Health (PRTC) Competitors

$17.42 0.00 (0.00%)

As of 06/22/2026

Compare

PRTC vs. AMLX, PVLA, SRPT, SNDX, and SEPN

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Amylyx Pharmaceuticals (AMLX), Palvella Therapeutics (PVLA), Sarepta Therapeutics (SRPT), Syndax Pharmaceuticals (SNDX), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does PureTech Health compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Amylyx Pharmaceuticals has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Amylyx Pharmaceuticals' score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals currently has a consensus price target of $23.00, suggesting a potential upside of 40.50%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Amylyx Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PureTech Health's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
PureTech Health	N/A	N/A	N/A

PureTech Health has lower revenue, but higher earnings than Amylyx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	20.83	-$144.74M	-$1.50	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Summary

Amylyx Pharmaceuticals beats PureTech Health on 8 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Palvella Therapeutics?

PureTech Health (NASDAQ:PRTC) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

PureTech Health's return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Palvella Therapeutics	N/A	-56.87%	-42.50%

In the previous week, Palvella Therapeutics had 6 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Palvella Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Palvella Therapeutics' score of 0.46 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Palvella Therapeutics	$42.81M	39.75	-$41.72M	-$4.17	N/A

Palvella Therapeutics has a consensus price target of $199.53, indicating a potential upside of 68.13%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the broader market.

Summary

Palvella Therapeutics beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

PureTech Health has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
PureTech Health	N/A	N/A	N/A

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Sarepta Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Sarepta Therapeutics and 1 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.72 beat Sarepta Therapeutics' score of 0.61 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has lower revenue, but higher earnings than Sarepta Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.83	-$713.41M	-$0.96	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Sarepta Therapeutics presently has a consensus target price of $24.81, indicating a potential upside of 43.74%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.08
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sarepta Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Summary

Sarepta Therapeutics beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Syndax Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Syndax Pharmaceuticals presently has a consensus target price of $42.55, indicating a potential upside of 116.96%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Syndax Pharmaceuticals is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has lower revenue, but higher earnings than Syndax Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.08	-$285.42M	-$2.79	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

0.0% of PureTech Health shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 1 mentions for PureTech Health. Syndax Pharmaceuticals' average media sentiment score of 1.57 beat PureTech Health's score of 0.72 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. PureTech Health's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
PureTech Health	N/A	N/A	N/A

Summary

PureTech Health beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Septerna?

PureTech Health (NASDAQ:PRTC) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Septerna has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

Septerna has a consensus price target of $45.78, suggesting a potential upside of 25.18%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

0.0% of PureTech Health shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Comparatively, 5.8% of Septerna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Septerna has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Septerna	$72.26M	22.81	-$48.88M	-$0.81	N/A

In the previous week, Septerna had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Septerna and 1 mentions for PureTech Health. Septerna's average media sentiment score of 1.16 beat PureTech Health's score of 0.72 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health has a net margin of 0.00% compared to Septerna's net margin of -49.88%. PureTech Health's return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Septerna	-49.88%	-12.72%	-8.87%

Summary

Septerna beats PureTech Health on 10 of the 15 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$424.04M	$3.45B	$6.44B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	N/A	19.75	24.67	23.99
Price / Sales	91.01	330.65	528.41	106.93
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.38	8.29	10.76	6.50
Net Income	-$109.74M	$23.85M	$3.56B	$336.88M
7 Day Performance	N/A	2.87%	1.03%	-0.14%
1 Month Performance	N/A	2.19%	0.45%	0.77%
1 Year Performance	-2.13%	55.48%	29.69%	28.49%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	0.7708 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
AMLX Amylyx Pharmaceuticals	2.0649 of 5 stars	$15.05 -0.9%	$23.00 +52.8%	+226.1%	$1.69B	$87.37M	N/A	200	News Coverage
PVLA Palvella Therapeutics	2.7013 of 5 stars	$110.12 -5.5%	$199.53 +81.2%	+426.5%	$1.67B	$42.81M	N/A	N/A	Insider Trade Gap Up
SRPT Sarepta Therapeutics	3.0053 of 5 stars	$15.78 +0.1%	$24.77 +57.0%	-8.5%	$1.66B	$2.20B	N/A	1,372
SNDX Syndax Pharmaceuticals	3.6454 of 5 stars	$18.55 +0.4%	$42.55 +129.4%	+113.4%	$1.64B	$217.17M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. AMLX, PVLA, SRPT, SNDX, and SEPN

How does PureTech Health compare to Amylyx Pharmaceuticals?

Summary

How does PureTech Health compare to Palvella Therapeutics?

Summary

How does PureTech Health compare to Sarepta Therapeutics?

Summary

How does PureTech Health compare to Syndax Pharmaceuticals?

Summary

How does PureTech Health compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. AMLX, PVLA, SRPT, SNDX, and SEPN

How does PureTech Health compare to Amylyx Pharmaceuticals?

Which has more risk and volatility, AMLX or PRTC?

Does the media prefer AMLX or PRTC?

Do analysts recommend AMLX or PRTC?

Do insiders and institutionals have more ownership in AMLX or PRTC?

Is AMLX or PRTC more profitable?

Which has better earnings & valuation, AMLX or PRTC?

Summary

How does PureTech Health compare to Palvella Therapeutics?

Is PRTC or PVLA more profitable?

Does the media refer more to PRTC or PVLA?

Do insiders and institutionals believe in PRTC or PVLA?

Which has better valuation & earnings, PRTC or PVLA?

Do analysts recommend PRTC or PVLA?

Which has more volatility & risk, PRTC or PVLA?

Summary

How does PureTech Health compare to Sarepta Therapeutics?

Is SRPT or PRTC more profitable?

Do institutionals and insiders hold more shares of SRPT or PRTC?

Does the media favor SRPT or PRTC?

Which has better earnings & valuation, SRPT or PRTC?

Do analysts rate SRPT or PRTC?

Which has more risk and volatility, SRPT or PRTC?

Summary

How does PureTech Health compare to Syndax Pharmaceuticals?

Which has more volatility and risk, SNDX or PRTC?

Do analysts recommend SNDX or PRTC?

Which has preferable earnings and valuation, SNDX or PRTC?

Do institutionals & insiders believe in SNDX or PRTC?

Does the media prefer SNDX or PRTC?

Is SNDX or PRTC more profitable?

Summary

How does PureTech Health compare to Septerna?

Which has more volatility and risk, PRTC or SEPN?

Do analysts recommend PRTC or SEPN?

Do insiders & institutionals have more ownership in PRTC or SEPN?

Which has stronger earnings and valuation, PRTC or SEPN?

Does the media refer more to PRTC or SEPN?

Is PRTC or SEPN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools